Erratum: Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab (British Journal of Cancer (2011) 104 (68-74) DOI: 10.1038/sj.bjc.6605972);Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab

British Journal of Cancer

Volumn 104, Issue 1, 2011, Pages 68-74

  Gualberto, A ^a,b   Hixon, M L ^b   Karp, D D ^c   Li, D ^a   Green, S ^a   Dolled Filhart, M ^d   Paz Ares, L G ^e   Novello, S ^f   Blakely, J ^g   Langer, C J ^h   Pollak, M N ⁱ  

^a Pf Izer Oncology ^*  (United States)

^b BROWN UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d HistoRx   (United States)

^e HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^f UNIVERSITY OF TURIN   (Italy)

^g WEST CLINIC   (United States)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ MCGILL UNIVERSITY   (Canada)

Author keywords

figitumumab; IGF 1; IGF IR; NSCLC

Indexed keywords

CARBOPLATIN; FIGITUMUMAB; INSULIN; PACLITAXEL; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; UVOMORULIN; VIMENTIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; INSULIN BLOOD LEVEL; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL;

EID: 78650858388     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.497     Document Type: Erratum

References (36)

1. Attia N, Caprio S, Jones TW, Heptulla R, Holcombe J, Silver D, Sherwin RS, Tamborlane WV (1999) Changes in free insulin-like growth factor-1 and leptin concentrations during acute metabolic decompensation in insulin withdrawn patients with type 1 diabetes. J Clin Endocrinol Metab 84: 2324-2328
2. Bereket A, Lang CH, Blethen SL, Ng LC, Wilson TA (1996) Insulin treatment normalizes reduced free insulin-like growth factor-I concentrations in diabetic children. Clin Endocrinol (Oxf) 45: 321-326
3. Borai A, Livingstone C, Ferns GA (2007) The biochemical assessment of insulin resistance. Ann Clin Biochem 44: 324-342
4. Brugts MP, Ranke MB, Hofland LJ, van der Wansem K, Weber K, Frystyk J, Lamberts SW, Janssen JA (2008a) Normal values of circulating insulinlike growth factor-I bioactivity in the healthy population: comparison with five widely used IGF-1 immunoassays. J Clin Endocrinol Metab 93: 2539-2545
5. BrugtsMP, van den Beld AW, Hofland LJ, van derWansemK, van Koetsveld PM, Frystyk J, Lamberts SW, Janssen JA (2008b) Low circulating insulinlike growth factor I bioactivity in elderly men is associated with increased mortality. J Clin Endocrinol Metab 93: 2515-2522
6. Brugts MP, van Duijn CM, Hofland LJ, Witteman JC, Lamberts SW, Janssen JA (2010) Igf-I bioactivity in an elderly population: relation to insulin sensitivity, insulin levels, and the metabolic syndrome. Diabetes 59: 505-508
7. Chang YS, Kong G, Sun S, Liu D, El-Naggar AK, Khuri FR, Hong WK, Lee HY (2002) Clinical significance of insulin-like growth factor-binding protein-3 expression in stage I non-small cell lung cancer. Clin Cancer Res 8: 3796-3802
8. Chitnis MM, Yuen JS, Protheroe AS, Pollak M, Macaulay VM (2008) The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res 14: 6364-6370
9. Cohen BD, Baker DA, Soderstrom C, Tkalcevic G, Rossi AM, Miller PE, Tengowski MW, Wang F, Gualberto A, Beebe JS, Moyer JD (2005) Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res 11: 2063-2073
10. Dubaquié Y, Lowman HB (1999) Total alanine-scanning mutagenesis of insulin-like growth factor I (IGF-1) identifies differential binding epitopes for IGFBP-1 and IGFBP-3. Biochemistry 38: 6386-6396
11. Dubaquié Y, Mortensen DL, Intintoli A, Hogue DA, Nakamura G, Rancatore P, Lester P, Sadick MD, Filvaroff E, Fielder PJ, Lowman HB (2001) Binding protein-3-selective insulin-like growth factor I variants: engineering, biodistributions, and clearance. Endocrinology 142: 165-173
12. Favoni RE, de Cupis A, Ravera F, Cantoni C, Pirani P, Ardizzoni A, Noonan D, Biassoni R (1994) Expression and function of the insulin like growth factor 1 system in human non small cell lung cancer and normal lung cell lines. Int J Cancer 56: 858-866
13. Frystyk J (2007) Utility of free IGF-1 measurements. Pituitary 10: 181-187
14. Gualberto A (2010) Figitumumab (CP-751,871) for cancer therapy. Expert Opin Biol Ther 10: 575-585
15. Gualberto A, Dolled-Filhart MP, Hixon ML, Christensen J, Rimm DL, Lee AV, Wang Y, Pollak M, Paz-Ares LG, Karp DD (2009) Molecular basis for sensitivity to figitumumab (CP-751,871) in NSCLC. J Clin Oncol 27: 15s (abstract 8091
16. Gualberto A, Pollak M (2009) Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene 28: 3009-3021
17. Han JY, Choi BG, Choi JY, Lee SY, Ju SY (2006) The prognostic significance of pretreatment plasma levels of insulin-like growth factor (IGF)-1, IGF-2, and IGF binding protein-3 in patients with advanced non-small cell lung cancer. Lung Cancer 54: 227-234
18. Janssen JA, Stolk RP, Pols HA, Grobbee DE, Lamberts SW (1998) Serum total IGF-1, free IGF-1, and IGFB-1 levels in an elderly population: relation to cardiovascular risk factors and disease. Arterioscler Thromb Vasc Biol 18: 277-282
19. Jassem J, Langer CJ, Karp DD, Mok T, Benner RJ, Green SJ, Park K, Novello S, Strausz J, Gualberto A (2010) Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC). J Clin Oncol 28: 15s (abstract 7500
20. Julien-Grille S, Moore R, Denat L, Morali OG, Delmas V, Bellacosa A, Laure L (eds(2005) The role of insulin-like growth factors in the epithelial to mesenchymal transition. In: Rise and Fall of Epithelial Phenotype: Concepts of Epithelial. Eurekah/Landes Bioscience: Georgetown
21. Juul A, Holm K, Kastrup KW, Pedersen SA, Michaelsen KF, Scheike T, Rasmussen S, Müller J, Skakkebaek NE (1997) Free insulin-like growth factor I serum levels in 1430 healthy children and adults, and its diagnostic value in patients suspected of growth hormone deficiency. J Clin Endocrinol Metab 82: 2497-2502
22. Kalluri R, Weinberg RA (2009) The basics of epithelial-mesenchymal transition. J Clin Invest 119: 1420-1428
23. Karp DD, Paz-Ares LG, Novello S, Haluska P, Garland L, Cardenal F, Blakely LJ, Eisenberg PD, Langer CJ, Blumenschein Jr G, Johnson FM, Green S, Gualberto A (2009) Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol 27: 2516-2522
24. Kelley KM, Oh Y, Gargosky SE, Gucev Z, Matsumoto T, Hwa V, Ng L, Simpson DM, Rosenfeld RG (1996) Insulin-like growth factor-binding proteins (IGFBPs) and their regulatory dynamics. Int J Biochem Cell Biol 28: 619-637
25. Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, Holmes AJ, Choi HG, Kim J, Chiang D, Thomas R, Lee J, Richards WG, Sugarbaker DJ, Ducko C, Lindeman N, Marcoux JP, Engelman JA, Gray NS, Lee C, Meyerson M, Jänne PA (2008) EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 14: 4275-4283
26. Lee PD, Conover CA, Powell DR (1993) Regulation and function of insulinlike growth factor binding protein-1. Proc Soc Exp Biol Med 204: 4-29
27. Morali OG, Delmas V, Moore R, Jeanney C, Thiery JP, Larue L (2001) IGF-2 induces rapid beta-catenin relocation to the nucleus during epithelium to mesenchyme transition. Oncogene 20: 4942-4950
28. Sakai K, D'Ercole AJ, Murphy LJ, Clemmons DR (2001) Physiological differences in insulin-like growth factor binding protein-1 (IGFBP-1) phosphorylation in IGFBP-1 transgenic mice. Diabetes 50: 32-38
29. Playford MP, Bicknell D, Bodmer WF, Macaulay VM (2000) Insulin-like growth factor 1 regulates the location, stability, and transcriptional activity of beta-catenin. Proc Natl Acad Sci USA 9: 12103-12108
30. Pollak M (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8: 915-928
31. Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A (2009) Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 101: 1308-1324
32. Sauter G, Lee J, Bartlett JM, Slamon DJ, Press MF (2009) Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 27: 1323-1333
33. Shepherd FA, Tsao MS (2010) Epidermal growth factor receptor biomarkers in non-small-cell lung cancer: a riddle, wrapped in a mystery, inside an enigma. J Clin Oncol 28: 903-905
34. Spitz MR, Barnett MJ, Goodman GE, Thornquist MD, Wu X, Pollak M (2002) Serum insulin like growth factor (IGF) and IGF binding protein levels and risk of lung cancer: a case control study nested in the beta carotene and retinol efficacy trial cohort. Cancer Epidemiol Biomarkers Prev 11: 1413-1418
35. Wolpin BM, Meyerhardt JA, Chan AT, Ng K, Chan JA, Wu K, Pollak MN, Giovannucci EL, Fuchs CS (2009) Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer. 27: 176-185
36. Zweig MH, Campbell G (1993) Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 39: 561-577